BGNE BeiGene, Ltd.

+2  (4%)
Previous Close 37.61
Open 37.81
Price To book 3.80
Market Cap 1.40B
Shares 35,663,000
Volume 84,431
Short Ratio 10.02
Av. Daily Volume 101,637

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 preliminary data to be presented at ASCO June 5, 2017. Abstract 3013.
BGB-A317 and BGB-290
Solid tumors
Phase 3 dosing of China based trial announced March 2, 2017.
Relapsed or refractory mantle cell lymphoma (MCL)
Phase 3 trial initiation announced January 25, 2017.
Waldenström’s macroglobulinemia

Latest News

  1. BeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting
  2. BeiGene Announces Initiation of First Pivotal Study in China of PD-1 Antibody BGB-A317
  3. BeiGene Presents Phase IB Data on RAF Dimer Inhibitor BGB-283 at the 2017 American Association for Cancer Research Annual Meeting
  4. Blog Coverage Agenus Announced Restructuring of Business
  5. BeiGene Ltd. :BGNE-US: Earnings Analysis: 2016 By the Numbers : March 24, 2017
  6. BeiGene Reports Fourth Quarter and Full Year 2016 Financial Results
  7. BeiGene Announces Initiation of Pivotal Study in China with BTK Inhibitor BGB-3111 in Patients with Relapsed or Refractory CLL/SLL
  8. BeiGene and Guangzhou Development District Establish Joint Venture to Build Biologics Manufacturing Facility
  9. BeiGene Announces Presentation of Phase IB Data on BGB-283 at the 2017 American Association for Cancer Research Annual Meeting
  10. BeiGene Announces Initiation of First Pivotal Study in China with BTK Inhibitor BGB-3111
  11. BeiGene to Present at the Cowen and Company 37th Annual Health Care Conference
  12. BeiGene to Participate in the LEERINK Partners 6th Annual Global Healthcare Conference
  13. Beigene Ltd (ADR) (BGNE): Here’s Our Take
  14. Do Hedge Funds Love Nobilis Health Corp (USA) (HLTH)?
  15. Should You Add Hawaiian Telcom HoldCo Inc (HCOM) to Your Portfolio?
  16. Is Federated National Holding Co (FNHC) A Good Stock To Buy?
  17. BeiGene (BGNE): Strong Industry, Solid Earnings Estimate Revisions

SEC Filings

  1. 8-K - Current report 17774273
  2. 8-K - Current report 17763410
  3. 8-K - Current report 17732533
  4. S-8 - Securities to be offered to employees in employee benefit plans 17707133
  5. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17707115
  6. 8-K - Current report 17707007
  7. 8-K - Current report 17678757
  8. 8-K - Current report 17669602
  9. 8-K - Current report 17658938
  10. SC 13G - Statement of acquisition of beneficial ownership by individuals 17600463